2022
Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes
Potashman M, Mize M, Beiner M, Pierce S, Coric V, Schmahmann J. Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes. The Cerebellum 2022, 22: 1257-1273. PMID: 36495470, PMCID: PMC10657309, DOI: 10.1007/s12311-022-01494-1.Peer-Reviewed Original ResearchConceptsClinical outcome assessmentPatient reported symptomsImpact of illnessPatient experienceAtaxia Rating ScaleReported symptomsRating ScaleAtaxia patientsPatients/familiesMuscle discomfortMotor syndromeCerebellar motor syndromeClinician assessmentOutcome measuresClinical measuresInvoluntary movementsPatientsOutcome assessmentCerebellar ataxiaSymptomsVision impairmentMuscle controlAtaxiaHand coordinationReal-life impact
2021
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
Johnston K, L’Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton R. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Advances In Therapy 2021, 38: 5209-5220. PMID: 34455556, PMCID: PMC8478726, DOI: 10.1007/s12325-021-01897-2.Peer-Reviewed Original ResearchConceptsMonthly migraine daysPRN groupMigraine-Specific QualityEQ-5DPRN armLong-term safety studiesHealth state utilitiesMigraine daysEpisodic migraineMethodsStudy participantsTreatment regimensWeek 12Study visitNeurological conditionsSafety studiesBaselineDay scheduleState utilitiesPatientsUtility valuesPRNOutcomesQODGroupDays
2020
Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials (2114)
Croop R, Jensen C, Thiry A, Stock E, Conway C, Morris B, Coric V, Lipton R. Rimegepant is Effective for the Acute Treatment of Migraine in Patients Who Have Discontinued or Currently Use Triptans: Results from 3 Phase 3 Clinical Trials (2114). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2114.Peer-Reviewed Original Research
2005
Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.Peer-Reviewed Original ResearchConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleY-BOCS scoresTreatment-resistant OCD patientsAddition of riluzolePractical clinical benefitOpen-label trialGlutamate-modulating agentsSerious adverse effectsHamilton Depression InventoryAnxiety Inventory scoresObsessive Compulsive ScaleMost patientsStandard therapyGlutamatergic dysfunctionAugmentation therapyClinical benefitPrimary diagnosisStandard treatmentCorticostriatal pathwayTreatment respondersRiluzolePatientsDepression Inventory
1998
Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase
Coric V, Oren D, Wolkenberg F, Kravitz R. Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase. Journal Of Neurology Neurosurgery & Psychiatry 1998, 65: 245. PMID: 9703180, PMCID: PMC2170185, DOI: 10.1136/jnnp.65.2.245.Peer-Reviewed Original ResearchConceptsHyperbaric oxygenCarbon monoxide poisoningPatient underwent treatmentAnterograde memory lossCarbon monoxide intoxicationCarbon monoxide exposureAcute confusionNeuropsychiatric functionSubacute phaseSymptom reliefUnderwent treatmentClinical findingsNormobaric oxygenImmediate treatmentBrain injuryTherapeutic windowNeuropsychological testingMatter of debateMemory lossPartial retrogradeTreatmentMonthsPoisoningNormobaricPatients